IRVINE, Calif.--(BUSINESS WIRE)--Cobalis Corp. (OTCBB:CLSC), a pharmaceutical development company specializing in anti-allergy medications, today reported that further review of the results from two Phase III clinical trials for its drug PreHistin™ in patients with seasonal allergic rhinitis, commonly known as hay fever, demonstrated a significant average increase of more than 250% in post-treatment blood serum cobalamin (Vitamin B12) levels across two PreHistin-treated patient groups compared with essentially no B12 level increase in placebo-treated patients.
